Updated: Acadia wins first FDA approval for Rett syndrome drug

Paul Schloesser

Associate Editor

Drew Armstrong

Executive Editor

The FDA on Friday approved Acadia Pharmaceuticals’ treatment for Rett syndrome, a rare neurodevelopmental disorder, which will be sold under the brand name Daybue …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Acadia wins first FDA approval for Rett syndrome drug

Paul Schloesser

Associate Editor

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?

Up­dat­ed: Aca­dia wins first FDA ap­proval for Rett syn­drome drug

Associate Editor

Executive Editor

Sign up to read this article for free.

Updated: Acadia wins first FDA approval for Rett syndrome drug